Key Takeaways for IDEXX Laboratories Stock
- Revenue grew 14% as reported to $1,140.82 million in Q1 2026, beating Street estimates of $1,108.83 million.
- Gross margins reached 63% in Q1 2026, up from 62% in Q1 2025, while operating income grew 15% year-over-year on a comparable basis.
- IDEXX stock’s full-year 2026 revenue guidance was raised to $4.675 billion to $4.760 billion, with EPS guidance increased to $14.45 to $14.90.
- TIKR’s mid-case values IDEXX stock at approximately $909 by December 2030, implying around 57% total return from the current price of $579.
IDEXX Stock Posts 14% Revenue Growth in Q1 2026 as Diagnostics Utilization Outpaces a Soft Visit Market
IDEXX Laboratories (IDXX), the global leader in veterinary diagnostics and animal health software, delivered what CFO Andrew Emerson called “exceptional financial results” in Q1 2026, growing revenue 14% as reported to $1,140.82 million while earning $3.47 per share, a 15% comparable increase that beat the Street consensus of $3.41.
The headline numbers obscure the more important story: IDEXX delivered 11% organic revenue growth in a quarter where U.S. same-store clinical visits declined 1%.
That gap is the mechanism. Companion Animal Group Diagnostics recurring revenues grew more than 11% organically while U.S. clinic traffic moved the other direction, a 1,100 basis point premium the CFO attributed directly to expanded diagnostic frequency and utilization per visit.
International CAG Diagnostics recurring revenues grew 12% organically, reflecting long-term investments in commercial expansion and localized software solutions that are now compounding into a durable installed base advantage.
The inVue Dx platform continues to be the single most visible growth engine. IDEXX placed 1,100 inVue Dx analyzers in Q1, putting the company on track for its 5,500 full-year placement target, with premium instrument revenues up 28% organically.
New CEO Mike Erickson, who took the role after Jay Mazelsky transitioned to Executive Chair following the annual meeting, laid out the strategic priority clearly at the Stifel Jaws & Paws Conference: “We’re already comfortably in that band with where that band for, as a reminder, included blood, ear and FNA. But we’re in that band today with blood and ear.”
The FNA (fine needle aspirate) module, which enables AI-powered cytology for lumps and bumps during the practice visit, is in controlled rollout and will move to an unconstrained launch in the second half of 2026, providing a second leg of per-instrument revenue expansion before the year closes.
Cancer Dx, IDEXX’s early cancer detection panel for canine lymphoma, now has 7,500 practices ordering since launch, with 70% of tests run as part of a broader blood panel, validating the pull-through strategy for reference lab volumes.
See how IDEXX stock’s CAG Diagnostics growth stacks up against historical trends on TIKR for free →
IDEXX Stock’s Gross Margin Expansion at 63% Proves the Recurring Revenue Flywheel Is Working
IDEXX Laborties stock’s gross margin reached 63% in Q1 2026, up from 62% in the same quarter of 2025, continuing a recovery from the 60% trough recorded in Q4 2024.
The driver is structural: consumable revenues tied to the installed premium instrument base grew 15% organically in Q1, and reference lab volumes accelerated, with the CFO crediting both net new customer gains and same-store utilization growth as each doubling from prior year levels.
IDEXX stock’s operating income grew from $315.61 million in Q1 2025 to $362.59 million in Q1 2026, a 15% increase, while the operating margin reached 32% for Q1 2026.
The sequence from Q2 2024 through Q1 2026 shows the flywheel compressing and then re-expanding: operating margins moved from 26% in Q2 2024 to 32% in Q3 2024, retreated to 27% in Q4 2024, rebuilt to 32% in Q1 2025, expanded to 34% in Q2 2025, and are now holding at 32% in Q1 2026, with Q2 2026 guidance calling for 34% operating margins.
Total operating expenses in Q1 2026 were $0.36 billion, matching the Q2 2024 level despite revenues growing from $1.00 billion to $1.14 billion over that same span, a direct demonstration of operating leverage beginning to assert itself.
SG&A rose from $0.25 billion in Q1 2025 to $0.29 billion in Q1 2026, and R&D held at $0.07 billion, consistent with the company’s stated investment in global commercial expansion and innovation capabilities. Those investments have not compressed margins because gross profit grew faster: gross profit was $0.72 billion in Q1 2026 versus $0.62 billion in Q1 2025, a 16% increase that absorbed the incremental opex and still produced margin expansion.
IDEXX Trades at a Structural Gross Margin Discount to Merck and Zoetis, and the Gap Is the Thesis
IDEXX stock’s gross margin of 63% in Q1 2026 sits roughly 13 percentage points below Merck’s (MRK) 76% and roughly 8 percentage points below Zoetis’s (ZTS) 72% over the same period, a persistent gap that has held consistently across every quarter from Q2 2024 through Q1 2026.
The gap is not narrowing. Merck’s gross margin ranged from 77% in Q2 2024 to 76% in Q1 2026, while Zoetis held between 70% and 74% across the same eight quarters, and IDEXX moved between 60% and 63%, never closing the distance by more than a point in either direction.
The implication for IDEXX stock’s investment case is precise: IDEXX earns its growth premium through volume compounding and installed base expansion, not through the pricing power or product mix that drives Merck’s and Zoetis’s structurally higher gross margins, which means the operating leverage story depends entirely on recurring revenue growing faster than operating expenses, a dynamic Q1 2026 confirmed but which requires continued execution to sustain.
Is IDEXX Stock Undervalued in 2026? TIKR’s $909 Model Says Yes, If the Recurring Revenue Flywheel Holds
TIKR’s base case values IDEXX Laboratories at approximately $909 by December 2030, implying around 57% total return from the current price of $579, or roughly 10% annualized over approximately 4.6 years.
If revenue compounds at around 8% and net income margins expand toward 26% as the installed base matures, the TIKR mid-case target of approximately $909 is achievable, delivering around 8% annualized returns with moderate P/E multiple contraction already assumed.
If execution accelerates and the FNA rollout drives per-instrument revenues toward the upper end of the $3,500 to $5,500 range that management has communicated, the TIKR high case reaches approximately $1,411, implying around 144% total return and around 11% annualized through December 2030.
If clinical visit declines deepen beyond the 1.5% baseline embedded in full-year guidance and recurring revenue growth slips to the low end of the 8% to 11% CAG Diagnostics range, the TIKR low case of approximately $892 still implies around 54% total return, or around 5% annualized over the same period.
Is IDEXX stock a buy right now?
IDEXX stock is trading at $579 against TIKR’s base-case target of approximately $909 by December 2030.
The income statement shows gross margins expanding to 63% in Q1 2026 while operating leverage is beginning to assert itself, with operating income growing 15% year-over-year on roughly 11% organic revenue growth.
The case for a buy rests on whether the recurring revenue flywheel tied to a 12% growing premium instrument installed base continues to compound faster than the soft visit environment can constrain it.
What is the IDEXX stock forecast for 2026?
Management raised full-year 2026 revenue guidance to $4.675 billion to $4.760 billion and EPS guidance to $14.45 to $14.90 following Q1 results, representing comparable EPS growth of 11% to 15%.
The raised guidance was supported by strong Q1 organic growth of 11% and a modestly improved clinical visit outlook, with U.S. visits now expected to decline 1.5% for the full year rather than the initial 2% baseline.
Should You Invest in IDEXX Laboratories, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up IDEXX Laboratories, Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track IDEXX Laboratories, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze IDXX stock on TIKR for Free →
